Ann: Appendix 4C and Quarterly Update, page-34

Morning LTS, but a recognised Commercial Valuation would provide a line in the sand demonstrating value to a 3rd party..

Current MC is $24m with $2m cash on hand leaves an EV of $22m.... I'm sure an independent Recognised Professional Valuation Company would be able to calculate a True Market Value with comparisons to other ASX Listed Biotechs...

IMHO PAA should be valued considerably higher than RAC ,, RAC have a single Repurposed Intravenous Oncology Treatment with an MC of $146m.
PAA with MPL has multiple Targets , Oncology, MND, HVTL-1, SARs 1 and SARs 2/ Covid.
PAA are extremely advanced having the Tablet already at GMP Grade , it's almost like having the Cart before the Horse,,, Tablet is completed and ready for Commercial size Manufacturing Runs,,,,, many times after Trialing Bespoke Treatments it can take well over a year to formulate a commercial run , in some cases that are Human Labour dependent you cant reduce the man hours or costs,,, that's why some infused drugs are $20,000 plus..

Management would be able to point to a number that the Market might take notice of???

Just saying its been at least 5 years since the Tech and Patents have been valued,,NZT


The Current SP and MC is now lower than when the MND Trial Began?? Before any type of confirmation that the Tablets were Tolerable and Soluble and deliver no adverse effects?? ,,couple that to a completed K9 Trial ,,, Maybe taking part in paid promotion on HC would be beneficial? Directly to ASX Investors? Emulate those that are successful , follow in footprints of those demonstrating success.....